We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Clears Salix Pharmaceuticals’ Relistor sNDA for New Indication
FDA Clears Salix Pharmaceuticals’ Relistor sNDA for New Indication
Salix Pharmaceuticals has convinced the FDA to reverse its 2012 stance blocking the company’s sNDA for an expanded use of its opioid-induced constipation drug Relistor.